Levodropropizine oral solution

This product is a peripheral antitussive drug, which exerts an antitussive effect by selectively inhibiting the peripheral C-fibers of the trachea and bronchus. Its site of action is at sites associated with sensory neuropeptides in the peripheral nodes. It has a strong antitussive effect and lasts for a long time. Since it has no effect on β-adrenergic receptors, M cholinergic receptors and opioid receptors, it has fewer adverse reactions of central inhibition and is an efficient and safe antitussive drug. Data from subacute and long-term toxicity tests on rats and dogs showed that the main phenomena during the medication period were salivation, decreased food intake and weight in rats, central sedation, peripheral vasodilation and increased heart rate in dogs; high doses were hepatotoxic to both animals. The test found that the maximum tolerated oral dose of the two animals was 24 mg/kg/d, which is 10 times the clinical dose. Levodropropizine has a slight effect only at 30 times the clinical dose.

Levodropropizine.

This product is a colorless clear solution; it tastes sweet and slightly astringent.

No data yet

Oral administration: 60 mg (1 vial) for adults, 30 mg (1/2 vial) for children aged 4 to 12 years old, the same as for adults for those over 12 years old; 3 times a day.

Adverse reactions are rare, mainly manifested as gastrointestinal reactions, nausea, upper abdominal pain, indigestion, vomiting, diarrhea, central nervous system reactions, fatigue, dizziness, drowsiness, headache, palpitations, dry mouth, etc., occasionally visual impairment, rash, dyspnea are rare. Transient elevation of transaminase can be seen at high doses.

1. Those who are known or may be allergic to this type of drug are prohibited from using this product. 2. Those who have a lot of sputum or impaired mucociliary clearance function are prohibited from using this product. 3. Pregnant women and lactating women are prohibited from using this product.

Precautions for children: Use with caution in children under 2 years old. Precautions for pregnancy and lactation: Pregnant and lactating women are prohibited. Precautions for the elderly: There is no significant change in the pharmacokinetics of elderly patients, and there is no need to adjust the dosage or change the interval between medications.

1. According to pharmacological studies on experimental animals, this product is rapidly absorbed by the nervous system. 2. It also affects the hypoglycemic effect of insulin and digestive system drugs. 3. For particularly sensitive patients, caution should be exercised when taking inhibitory drugs at the same time. 4. Clinical studies have not found any adverse effects on the simultaneous use of other drugs for the treatment of bronchopneumonia.

Keep away from light and store in a sealed container.

10ml:60mg;100ml/bottle

24 months

Mayinglong Pharmaceutical Group Co., Ltd.

• Founded in:

  1994-05-09

• Address:

  No. 100, Zhoujiawan, Nanhu, Wuchang, Wuhan, Hubei

• Tax NO.:

  91420100177701670K

• Registered Funds:

  431.053891 yuan

• Website:

  Log in to view

• Email:

  Log in to view